How the Narrative for Ascendis Pharma Is Evolving Amid New Analyst Optimism and Challenges

Ascendis Pharma’s consensus analyst price target has recently increased from $245.61 to $258.77 per share. This reflects a renewed sense of optimism as Yorvipath’s uptake accelerates and real-world ...
eLife

Apparent cooperativity between human CMV virions introduces errors in conventional methods of calculating multiplicity of infection

Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

Euro Sun Welcomes Romania’s Steps to Adopt the European Union’s Critical Raw Materials Act and Reports Stronger Project Economics With NPV Rising to US$1.78 …

Euro Sun Mining Inc., (TSX: ESM) (“Euro Sun”, “ESM”, or the “Company”) is delighted to announce that under an Emergency ...